Axio Lattice
A subscription model for connecting data across companies.
Connecting data across partners, sites and systems
Axio Lattice connects data across pharma and manufacturing partners to accelerate tech transfers and make that data usable for AI. Each company keeps its existing systems and control of its underlying records.
Fragmented manufacturing data is the quiet tax on every biologics program
Fragmented, siloed data between drug sponsors and CDMOs prevents AI from delivering real value and costs the industry months of delay per program.
Our business model
Axio Forge
High-throughput antibody production generating fee-for-service revenue.
Why a sponsor and a CDMO can both use Axio
-
01 — Neutrality
Independent of sponsors and CDMOs
Partners can connect their data without giving each other control of their underlying records.
-
02 — Reuse
Connections customers can reuse
Customers can reuse existing connections and approved mappings rather than start again for every program.
-
03 — Wet-lab engine
Experience from our own lab
Forge generates service revenue. We use Lattice there to connect our laboratory instruments and data.
Axio's founders come from process development and bioinformatics
-
Justin Byers
Founder, CEO
Biopharma PD and commercial leader focused on building biomanufacturing services from the ground up.
-
Brian Staats
Co-founder, CTO
Technology leader specializing in bioinformatics with 20+ years in modeling, data science, and engineering.
Request investor materials
Tell us what information you need about an investment in Axio.